Skip to content

COPD genetics and alpha-1 antitrypsin deficiency

TL;DR — COPD susceptibility is polygenic and exposure-dependent; common-variant associations map lung development, nicotine dependence, airway biology and emphysema but do not yet support routine polygenic prescribing (Silverman 2020, PMID 31730394). SERPINA1 deficiency is the clinically actionable exception: severe alpha-1 antitrypsin deficiency (AATD) increases early emphysema risk and can cause liver disease (Greene 2016, PMID 27465791). COPD should prompt at least one AATD test because targeted testing alone misses cases (Miravitlles 2017, PMID 29191952). Genotype/phenotype confirmation, family testing and exposure removal are central; intravenous augmentation slows CT-density loss in selected severe deficiency, while survival evidence remains observational (Fraughen 2023, PMID 37624745).

Genetic architecture

Twin/family observations and genome-wide studies show heritable variation in lung function and COPD risk, but no single common variant determines disease (Silverman 2020, PMID 31730394). Genetic effects interact with smoking, pollution, infections and attained lung growth.

Genetic layer Example Clinical readiness
Rare high-impact variant Pathogenic SERPINA1 alleles Diagnostic testing and family cascade
Common susceptibility loci Lung-function/COPD GWAS loci Research stratification
Nicotine-dependence loci Exposure intensity and cessation biology Not a COPD diagnostic test
Epigenetic state Exposure-linked methylation/expression Confounding and reverse causation remain
Polygenic score Aggregate common variants No validated prescribing threshold

COPDGene was designed to integrate genotype, spirometry, CT phenotypes and longitudinal outcomes, recognizing that a binary COPD label discards biological information (Regan 2010, PMID 20214461). Reviews of COPD genetics emphasize both replicated loci and the gap from association to mechanism (Marciniak 2014, PMID 24507835; Silverman 2020, PMID 31730394).

Alpha-1 antitrypsin biology

Alpha-1 antitrypsin is a circulating serine-protease inhibitor produced mainly by hepatocytes. Severe deficiency reduces protection from neutrophil elastase in the lung; polymer accumulation of some variants injures liver cells (Greene 2016, PMID 27465791).

Feature Lung implication Liver implication
Low circulating AAT Protease–antiprotease imbalance Does not itself define hepatic injury
Z-protein polymerization Severe deficiency when homozygous Intracellular retention and disease risk
Cigarette smoke Oxidant burden and accelerated emphysema Adds overall risk rather than polymer mechanism
Occupational inhalants Additional lung injury Exposure reduction remains essential
Family inheritance Siblings/offspring may carry variants Cascade testing can identify both organ risks

Who should be tested?

Respiratory-society guidance supports testing people with COPD and other suggestive phenotypes rather than limiting testing to young nonsmokers (Miravitlles 2017, PMID 29191952). Detection remains poor because age, smoking history or a typical upper-lobe pattern are incorrectly used to exclude AATD (Brantly 2020, PMID 32306990).

Testing trigger Reason
COPD/persistent obstruction Phenotype is insufficiently specific to rule AATD out
Emphysema at young age Raises pre-test probability
Basilar-predominant emphysema Classic but neither necessary nor sufficient
Unexplained bronchiectasis A recognized testing context
Necrotizing panniculitis or granulomatosis with polyangiitis Rare associated presentations
Unexplained liver disease Polymer-related hepatic phenotype
Affected relative Enables cascade detection

Testing sequence and interpretation

Serum AAT concentration is an entry test but is influenced by inflammation and pregnancy. Low or suspicious levels require qualitative phenotype and/or SERPINA1 genotyping; discordant cases may need sequencing (Greulich 2016, PMID 26341117).

Step Purpose Pitfall
AAT concentration Detect biochemical deficiency Acute-phase elevation can mask low baseline
Genotype for common alleles Identify S/Z and common variants Limited panels miss rare/null alleles
Protein phenotype Characterize circulating isoforms Interpretation needs concentration/context
Sequencing Resolve unexplained discordance Variants of uncertain significance
Family testing Find presymptomatic relatives Requires consent and counseling

Clinical phenotypes

Severe AATD classically causes panacinar emphysema, often basilar, but observed disease varies with smoking and other exposures (Stockley 2014, PMID 24507836). Bronchiectasis, asthma-like traits and chronic bronchitis may coexist. Liver disease can present in infancy or adulthood and does not track lung severity.

Heterozygous states carry context-dependent risk. A genotype label should not be translated into deterministic prognosis; exposure history, AAT concentration, physiology, CT and family history provide the actionable phenotype (Dasí 2024, PMID 37993348).

Management evidence

All COPD measures still apply: smoking avoidance/cessation, vaccination, bronchodilators when indicated, rehabilitation, exacerbation prevention and exposure control. Family identification is itself preventive because never-smoking relatives may preserve lung function.

Intravenous augmentation raises circulating and epithelial-lining-fluid AAT. Evidence supports reduced CT lung-density loss in selected adults with severe deficiency, but effects on exacerbations, quality of life and mortality are less certain (Strange 2018, PMID 29794204).

Intervention Evidence boundary
Intravenous augmentation Selected severe deficiency with emphysema; availability and criteria vary
Smoking cessation Essential; large biological rationale and general COPD outcome evidence
Inhaled therapy Treats COPD traits, not the inherited deficiency
Lung transplant End-stage lung disease; does not correct hepatic genotype
Liver transplant Corrects hepatic source; reserved for end-stage liver disease
Gene/RNA approaches Investigational

A multinational registry analysis associated augmentation therapy with improved survival, but treatment allocation was nonrandomized and survival appeared decoupled from spirometric decline (Fraughen 2023, PMID 37624745). This supports, but cannot replace, randomized outcome evidence.

Beyond SERPINA1

Common-variant research identifies pathways rather than clinical diagnoses. Loci can relate to maximal lung growth, airway caliber, emphysema distribution or smoking behavior; causal genes may not be the nearest genes (Silverman 2020, PMID 31730394).

Translation requires ancestry-diverse cohorts, functional validation, prospective calibration and evidence that risk disclosure or targeted intervention improves outcomes. Current cohorts remain disproportionately enriched for European ancestry.

Quantified genetic architecture

The 2014 multi-cohort GWAS combined 6,633 moderate-to-severe COPD cases with 5,704 controls, confirming CHRNA3, FAM13A and HHIP and identifying RIN3; the severe-disease analysis included 3,497 people and showed stronger effects near HHIP and CHRNA3 (Cho 2014, PMID 24621683). These loci implicate nicotine dependence, development, repair and matrix biology, but their individual effects are too small for deterministic clinical prediction (Silverman 2020, PMID 31730394). COPDGene’s imaging and physiological depth helps map genotype to emphysema/airway phenotypes, while its smoking and ancestry eligibility affect transportability (Regan 2010, PMID 20214461; Ragland 2019, PMID 30908940).

AATD augmentation: endpoints do not align

Evidence layer Result Interpretation
Biological rationale Severe SERPINA1 deficiency removes a major neutrophil-elastase inhibitor and produces a strong protease–antiprotease susceptibility (Greene 2016, PMID 27465791; Stockley 2014, PMID 24507836). One of the clearest causal molecular COPD subtypes.
RAPID randomized trial 60 mg/kg weekly A1PI versus placebo for 24 months in severe deficiency with FEV1 35–70% predicted; CT density at total lung capacity favored augmentation, whereas the combined TLC/FRC primary endpoint was less decisive (Chapman 2015, PMID 26026936). CT densitometry is more sensitive than spirometry but remains a surrogate.
Registry evidence Multinational observational analysis associated augmentation with improved survival (Fraughen 2023, PMID 37624745). Confounding by indication, access and survivor selection remain possible.
Guideline position ERS supports targeted diagnosis and specialist management (Miravitlles 2017, PMID 29191952). Eligibility and reimbursement differ by country.

RAPID and its extension are registered as NCT00261833 and NCT00670007; both records resolved as completed in the ClinicalTrials.gov v2 API on 2026-09-02. Trial completion does not answer whether augmentation reduces exacerbations, transplantation or mortality.

Testing and interpretation controversies

Question Position A Position B / unresolved issue
Who to test? Test all people with COPD at least once to reduce missed severe deficiency (Miravitlles 2017, PMID 29191952; Brantly 2020, PMID 32306990) Yield, laboratory access and cascade follow-through vary
Serum level alone? Fast and inexpensive Acute-phase elevation can mask deficiency; phenotype/genotype resolves discordance (Greulich 2016, PMID 26341117)
Heterozygotes Smoking avoidance and family counseling are biologically compelling Augmentation benefit is not established for common heterozygous states (Torres-Durán 2018, PMID 29996870)
Polygenic score Captures risk beyond SERPINA1 Calibration across ancestry and incremental utility over exposure/spirometry/CT remain inadequate (Silverman 2020, PMID 31730394)

The life-course framework complicates genetic attribution: low attained lung function and accelerated decline can both lead to COPD at similar tobacco exposure (Lange 2015, PMID 26154786), and genetic effects may act on growth, smoking behavior, airway structure or injury response rather than one final common pathway.

Broader genetic architecture and a hard AATD evidence boundary

A multi-ancestry lung-function GWAS of 580,869 participants identified 1,020 independent signals and implicated 559 genes by at least two mapping criteria; individual effects varied across ancestry, age and smoking strata even though the aggregate score associated with COPD across ancestry groups (Shrine 2023, PMID 36914875). PRISm is partly genetically continuous with COPD: a GWAS found 22 signals, four novel for lung function, genetic correlation with spirometric COPD of 0.62 and a smaller correlation with type-2 diabetes of 0.12 (Higbee 2024, PMID 38097206). These findings argue against treating preserved-ratio impairment as a purely mechanical precursor.

For AATD augmentation, a Cochrane synthesis of three randomized trials and 283 participants found slower CT-density loss (mean difference 0.86 g/L, 95% CI 0.31–1.42) but no established mortality, hospitalization, exacerbation or quality-of-life benefit; the review therefore did not recommend treatment on the available randomized evidence (Gøtzsche 2016, PMID 27644166). This directly conflicts with practice positions that accept CT density as a disease-progression endpoint and observational survival data. The unresolved question is not whether infused AAT reaches the lung, but whether the structural surrogate translates into outcomes that justify indefinite treatment burden and cost.

Genetic susceptibility extends beyond the obstructive ratio. In 8,372 population participants, DLCO heritability was 23–28% among unrelated and 45–49% among related people; a functional ADGRG6-region variant associated with DLCO/VA and pulmonary ADGRG6 expression was lower in COPD (Terzikhan 2018, PMID 30049742). A never-smoker GWAS replicated HHIP and FAM13A associations with FEV1/FVC without significant variant-by-smoking interaction, supporting susceptibility to obstruction that is not tobacco-dependent (van der Plaat 2017, PMID 27612410). Neither finding yet yields a clinically calibrated prediction tool.

From association signal to regulatory mechanism

An emphysema-pattern GWAS identified 10 loci and localized one signal to a regulatory region downstream of TGFB2. Chromatin-contact data connected the region to the TGFB2 promoter, and CRISPR/Cas9 deletion of an approximately 100-base-pair interval containing rs1690789 reduced TGFB2 expression in primary human lung fibroblasts (Parker 2019, PMID 31343404). This supplies a credible variant-to-cell-function chain, but neither the direction of effect in diseased tissue nor a safe therapeutic direction follows automatically from reduced expression in cultured fibroblasts.

Open questions

  • Which severe AATD patients gain survival or exacerbation benefit from augmentation, and at what cost? (Fraughen 2023, PMID 37624745)
  • Can dried-blood-spot reflex genotyping make universal COPD testing routine? (Brantly 2020, PMID 32306990)
  • How should rare SERPINA1 variants and discordant concentration/genotype results be classified? (Greulich 2016, PMID 26341117)
  • Can COPD polygenic scores add useful prediction across ancestries beyond spirometry, CT and exposure? (Silverman 2020, PMID 31730394)
  • Which GWAS loci are causal and therapeutically tractable? (Marciniak 2014, PMID 24507835)

References

  1. Silverman EK. Genetics of COPD. Annu Rev Physiol. 2020. PMID 31730394
  2. Greene CM, et al. Alpha-1 antitrypsin deficiency. Nat Rev Dis Primers. 2016. PMID 27465791
  3. Miravitlles M, et al. ERS statement: diagnosis and treatment of pulmonary disease in alpha-1 antitrypsin deficiency. Eur Respir J. 2017. PMID 29191952
  4. Regan EA, et al. Genetic epidemiology of COPD (COPDGene) study design. COPD. 2010. PMID 20214461
  5. Marciniak SJ, et al. Genetic susceptibility. Clin Chest Med. 2014. PMID 24507835
  6. Stockley RA. Alpha-1-antitrypsin review. Clin Chest Med. 2014. PMID 24507836
  7. Brantly M, et al. Detection of alpha-1 antitrypsin deficiency: past, present and future. Orphanet J Rare Dis. 2020. PMID 32306990
  8. Greulich T, et al. Alpha-1-antitrypsin deficiency: increasing awareness and improving diagnosis. Ther Adv Respir Dis. 2016. PMID 26341117
  9. Dasí F, et al. Alpha-1 antitrypsin deficiency. Med Clin (Barc). 2024. PMID 37993348
  10. Strange C. Anti-proteases and alpha-1 antitrypsin augmentation therapy. Respir Care. 2018. PMID 29794204
  11. Fraughen DD, et al. Augmentation therapy for severe AATD improves survival: a multinational registry analysis. Am J Respir Crit Care Med. 2023. PMID 37624745
  12. Torres-Durán M, et al. Alpha-1 antitrypsin deficiency: outstanding questions and future directions. Orphanet J Rare Dis. 2018. PMID 29996870
  13. Cho MH, et al. Risk loci for COPD: genome-wide association study and meta-analysis. Lancet Respir Med. 2014. PMID 24621683
  14. Ragland MF, et al. Genetic advances in COPD: insights from COPDGene. Am J Respir Crit Care Med. 2019. PMID 30908940
  15. Chapman KR, et al. RAPID augmentation therapy and lung density in severe AATD. Lancet. 2015. PMID 26026936
  16. Lange P, et al. Lung-function trajectories leading to COPD. N Engl J Med. 2015. PMID 26154786
  17. Shrine N, et al. Multi-ancestry genome-wide association analyses of lung function and COPD risk. Nat Genet. 2023. PMID 36914875
  18. Higbee DH, et al. Genome-wide association study of preserved-ratio impaired spirometry. Eur Respir J. 2024. PMID 38097206
  19. Gøtzsche PC, et al. Intravenous alpha-1 antitrypsin augmentation therapy for AATD lung disease. Cochrane Database Syst Rev. 2016. PMID 27644166
  20. Terzikhan N, et al. Heritability and genome-wide association study of diffusing capacity. Eur Respir J. 2018. PMID 30049742
  21. van der Plaat DA, et al. FEV1/FVC GWAS in never-smokers identifies HHIP and FAM13A. J Allergy Clin Immunol. 2017. PMID 27612410
  22. Parker MM, et al. Identification of an emphysema-associated genetic variant near TGFB2 with regulatory effects in lung fibroblasts. eLife. 2019. PMID 31343404